Merck & Co Financial Results
Merck reported third-quarter 2026 worldwide sales of $18.1 billion, representing 5% growth driven by strong performance in oncology and animal health. The company narrowed and raised its full-year 2026 sales outlook to a range of $66.8 billion to $67.3 billion and highlighted clinical progress in its late-stage pipeline, including pivotal data for sac-TMT and its therapeutic cancer vaccine collaboration with Moderna.
- Term
- Q3 2026
“Our science-led strategy is transforming our business. The potentially practice-changing advances in oncology presented at last weekend’s ESMO meeting, including new data for our antibody-drug conjugate sac-TMT and the first Phase 3 validation of a therapeutic cancer vaccine, further clinically de-risk the substantial long-term opportunity of our late-phase pipeline. With positive momentum across multiple therapeutic areas, I’m increasingly confident in our ability to deliver long-term value for patients and shareholders.”
Robert M. Davis, chairman and chief executive officer